VEIL.AI

🚀 Exciting news! Introduce first RWD optimized reference architecture fulfilling the European EHDS2 regulatory requirements 🇪🇺 BC Platforms, Modirum Platforms, VEIL.AI and Productivity Leap are partnering to create end-to-end reference architecture and data exchange formats for AI-enhanced software platform, which will streamline and automate EHDS2 processes for life sciences research use-cases using real-world data (RWD). The European Health Data Space (EHDS) is an EU-led initiative to create a unified digital health ecosystem across Europe, aiming to improve the way health data is accessed, shared, and used. It encompasses a legal framework of rules, common standards and practices, and infrastructures for healthcare data governance. The secondary framework (EHDS2) focuses on creating an efficient and trustworthy system for reusing health data for research, innovation, and public health improvements (secondary data use). VEIL.AI contributes next-generation anonymization, which transforms sensitive data into high quality, row-level, EHDS-compliant anonymized data. The technology ensures that critical data relationships are preserved even in anonymized datasets. “Under EHDS regulations, unless there are valid reasons to provide pseudonymized data, data must be released in anonymized form. Our AI-enhanced technology helps retain key data relationships even in anonymized formats,” said Tuomo Pentikäinen, CEO of VEIL.AI. Read full press release on BC Platform's website 👉 https://bit.ly/3C8AjZO #EHDS #EHDS2 #referencearchitecture #RWD #realworlddata #healthtech #lifescience #dataanonymization #dataexchange #innovation

Last month, VEIL.AI took part in two exciting U.S. events: BioTechX USA in Philadelphia (Sept. 17-18) and the Nordic Mentor Network For Entrepreneurship - NOME tech-enabling program in Boston (Sept. 23-27). Our key insights were that core issues of data privacy are similar in the U.S. and E.U., and that anonymization can enable data access for trans-Atlantic collaborations. Read our key takeaways here 👉 https://lnkd.in/dA8EKKEv #biotechx #NOME #transAtlantic #dataprivacy #dataanonymization #datasharing #datacollaboration #HIPPA #GDPR

Exciting news: VEIL.AI was selected as one of the finalists at the Health-X Innovation Forum and will continue developing the VEIL.AI Anonymization Engine as an EHDS-ready solution for Health-X dataLOFT ✌ VEIL.AI's next-generation anonymization is poised to become a key part of the Health-X data space, using extremely high-quality anonymized data to enable sharing of sensitive health data in a GDPR-compliant manner. Health-X dataLOFT is a consortium of 14 research, supply, and industry partners that focuses on sovereignty over personal health data and its secure digitalization. With the upcoming European Health Data Space (EHDS) regulation in the EU, it aims to create Health-X, a common decentralized data space where citizens can consent to share their health data from the primary and secondary healthcare market with doctors, clinics, and researchers without moving it into one centralized cloud platform. This achievement would not have been possible without our amazing team members Max Salmi and Susanne Hultsch, PhD 👏👏 Stay tuned as we work towards presenting the final results in March 2024! Check out the full news here 👉 https://lnkd.in/dEgg9qYz #HealthX #HealthDataSpace #EHDS #DataPrivacy #Innovation #VEILAI

VEIL.AI Denmark's CEO Lauri Kuronen and CTO Timo Miettinen had a fantastic time at LSX Nordic Congress in Copenhagen 🇩🇰 The LSX Nordic Congress connects life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalization of Nordic & Baltic life science and healthcare innovation. Thank the organizer for such an amazing conference! #LSXNordicCongress #nextgenerationanonymization #healthdataprivacy #datainnovation #dataanonymization #GDPRcompliance #EHDSready #VEILAI #funding

It was a blast! VEIL.AI's CEO Tuomo Pentikäinen was on stage to deliver an inspiring keynote at BioTechX Europe 2024, diving deep into the topical topic of building a privacy-preserving synthetic control arm and leveraging legacy RCT data. A key take-home message was the need to solve the privacy problem of sensitive data while preserving its quality. At VEIL.AI, we're pushing the boundaries of modern anonymization techniques to maintain extreme data quality without sacrificing data privacy. The classic problem with anonymization is that it destroys the data quality, utility, and fidelity. The problem arises from the fact that even with a relatively small dataset of a couple of thousands of patients and some tens or hundreds of variables, there are easily millions or even billions of feasible anonymization solutions. Feasible in the sense that they fulfill the given anonymity criteria (e.g. simple k=x anonymity or some given differential privacy requirement). However, the data quality implications of different anonymization solutions are often massive. Tuomo presented a study made with public breast cancer data in which we compared Kaplan-Meier survival models for original data, well-anonymized data, and standard anonymization mechanisms. The results were clear: standard anonymization tends to destroy the power and representativeness of data. With proper optimization, the loss can be minimized dramatically. In addition, Tuomo highlighted our successful collaboration with global life science Bayer in the Future Clinical Trials project, which utilized AI-enhanced next-generation anonymization from VEIL.AI. Our unique technology enabled the secure and efficient use of high-quality, anonymized data. For the first time, FinData approved the data as GDPR-compliant, allowing its transfer across borders for further innovative research. Data Quality and Data Privacy - you must (and can) deal with both! Interested in learning more? Schedule a meeting with our team through the event app or visit us at booth #928. Let’s explore how we can build a synthetic control arm and advance clinical trials together! #biotechX #keynote #nextgenerationanonymization #dataprivacy #syntheticcontrolarm #datasharing #bayer #pharma #clinicaltrials #rct #reusedata

Welcome to hear an inspirational keynote by Tuomo Pentikäinen at BioTechX! #biotechx #clinicaldatashare #clinicaltrials #anonymization

Don't miss VEIL.AI' CEO Tuomo Pentikäinen keynote tomorrow on the topic of building a privacy-preserving synthetic control arm and utilizing legacy RCT data at the BioTechX Europe 2024! ⏰ Wednesday, October 9, 2024 3:30 - 3:50 PM (Europe/Brussels) 📍 Theatre 7, Messe Basel, Switzerland Schedule a meeting with our team on the event app, or meet us at booth #928.  Looking forward to seeing many of you tomorrow! #biotechx #biotechxeu2024 #nextgenerationanonymization #dataprivacy #gdpr #ehds #pharma #clinicaltrial #datasharing #syntheticcontrolarm

Meet VEIL.AI at BioTechX EU 2024 on October 9-10! Discover how our next-generation anonymization generates high-quality individual-level anonymized and synthetic data – that is GDPR-compliant and EHDS-ready – providing valuable new possibilities for pharma and diagnostics companies, hospitals and all organizations utilizing sensitive health data for secondary use purposes. During the event, we will present our poster on VEIL.AI’s proprietary technology and showcase a real case of how we collaborated with Bayer to enable the creation of a synthetic control arm. In addition, on Wednesday October 9th, our CEO Tuomo Pentikäinen will be on stage to speak about "Building a Privacy-preserving Synthetic Control Arm and Utilizing Legacy RCT Data." Schedule a meeting with our team on the event app, or meet us at booth #928.  For more information about VEIL.AI's attendance, contact info@veil.ai #biotechx #biotechxeurope2024 #nextgenerationanonymization #dataprivacy #gdpr #ehds #pharma #clinicaltrial #datasharing #syntheticcontrolarm

We are thrilled to introduce VEIL.AI's refreshed brand identity! The renewed brand identity reflects our commitment to enable the use of sensitive health data and represents our evolution into a globally recognized leader in the field of health data privacy enhancing technologies. "This brand refresh represents an important step in VEIL.AI’s growth," said Tuomo Pentikäinen, CEO of VEIL.AI. "It’s not just about new visuals; it’s about presenting a more mature and evolved version of VEIL.AI. Our successful collaboration with global pharmaceutical leaders like Bayer, leading research hospitals like HUS, and health data permit authorities like Findata have positioned us as a leader in tackling the privacy challenges associated with sensitive health data. VEIL.AI’s next-generation anonymization technology allows us to offer high-quality, individual-level anonymized and synthetic data solutions that are both GDPR-compliant and EHDS-ready." With this refreshed identity, we aim to connect more deeply with our customers, partners, and stakeholders, delivering an even more cohesive and modern experience. Check out our new look at www.veil.ai and join us on this exciting journey as we continue to revolutionize how sensitive data is leveraged, respecting and protecting individual privacy 🚀 #brandrefresh #visualidentity #nextgenerationanonymization #healthdataprivacy #datainnovation #dataanonymization #GDPRcompliance #EHDSready #VEILAI

Last week VEIL.AI's CEO Tuomo Pentikäinen and CCO Juha Paakkola had the opportunity to participate in the Nordic Mentor Network For Entrepreneurship - NOME bootcamp in Boston 🇺🇸, hosted by the Innovation Centre Denmark Boston 🚀 Kudos to organizers, especially Jørn Emborg Daniel Blaesdahl Nielsen for the excellent planning and arrangements, and Peter Birk for coordinating on behalf of NOME. This has provided us with invaluable opportunities to connect with globally leading pharma and biotech companies! And thank you to our fellow alumnus Aplex Bio, NADMED Ltd., TRI Thinking Research Instruments GmbH, Inform Life, Kvantify for insightful discussions, feedback and fun! Highlights of the bootcamp: ⚡ Super insightful one-on-one and group meetings with over 10+ leading pharma and biotech companies. ⚡ Handpicked meetings with potential investors, providing a clear path for future collaboration. ⚡ Exciting interactions with public and semi-public holders of large health-related data sets. Key Takeaways: 💎 Sensitivity around data and privacy is just as important here in the U.S. as it is in Europe. 💎 Cross-Atlantic data collaboration, particularly in clinical research, is challenging due to data transfer restrictions. 💎 Re-use of data is complicated for several reasons, from informed consent to privacy issues. 💎 Anonymization is widely seen as a powerful tool to solve many of the data privacy problems. 💎 Anonymization's adverse impact on data quality and fidelity is a well-known problem. VEIL.AI's next-generation anonymization technology was seen as a super interesting and promising approach Looking forward to continuing discussions and deepening collaborations with many of the fantastic people and organizations we’ve connected with here in Boston. Follow-up meetings have already begun! 😉 Photos credit to  Innovation Centre Denmark Boston/ Innovation Centre Denmark. #NOME #Boston #bootcamp #LifeSciences #DataPrivacy #NextGenerationAnonymization #Pharma #Biotech #Innovation